Aug 10, 2026, 7:00 AM EDT · 1 month ago Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
2026-07-14T10:05:31.000Z · 2 months ago NextCure, Avere Therapeutics enter definitive merger agreement
2026-07-14T10:05:13.000Z · 2 months ago NextCure, Avere Therapeutics enter definitive merger agreement
Jul 14, 2026, 6:00 AM EDT · 2 months ago NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
Jun 4, 2026, 8:00 AM EDT · 4 months ago NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
2026-06-01T13:49:45.000Z · 4 months ago NextCure presents Phase 1 data for SIM0505 in gynecologic cancers
Jun 1, 2026, 8:00 AM EDT · 4 months ago NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
May 7, 2026, 4:05 PM EDT · 5 months ago NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-04T12:10:48.000Z · 5 months ago NextCure initiates dose optimization portion of SIM0505 study
May 4, 2026, 7:05 AM EDT · 5 months ago NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
Apr 21, 2026, 10:15 AM EDT · 5 months ago NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
Apr 7, 2026, 8:05 AM EDT · 6 months ago NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
Mar 31, 2026, 4:05 PM EDT · 6 months ago NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
Mar 5, 2026, 4:05 PM EST · 7 months ago NextCure Provides Business Update and Reports Full Year 2025 Financial Results
2026-01-23T12:05:31.000Z · 8 months ago NextCure expects SIM0505 Phase 1 dose escalation data update in Q2
2025-11-26T21:05:41.000Z · 10 months ago NextCure files to sell 2.52M shares of common stock for holders
Nov 20, 2025, 8:00 AM EST · 10 months ago NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
Nov 17, 2025, 8:00 AM EST · 10 months ago NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
Nov 12, 2025, 8:00 AM EST · 10 months ago NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
Nov 5, 2025, 4:05 PM EST · 11 months ago NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
Oct 16, 2025, 8:05 AM EDT · 11 months ago NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
Sep 4, 2025, 7:00 AM EDT · 1 year ago NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 7, 2025, 4:05 PM EDT · 1 year ago NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
Jul 24, 2025, 4:05 PM EDT · 1 year ago Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
Jun 16, 2025, 10:03 AM EDT · 1 year ago NextCure signs up to $745 million deal with China's Simcere to develop cancer drug
Jun 16, 2025, 7:05 AM EDT · 1 year ago NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
May 29, 2025, 4:05 PM EDT · 1 year ago NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
May 1, 2025, 4:05 PM EDT · 1 year ago NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
Apr 4, 2025, 7:00 AM EDT · 1 year ago NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
Mar 6, 2025, 4:05 PM EST · 1 year ago NextCure Provides Business Update and Reports Full Year 2024 Financial Results
Jan 10, 2025, 8:05 AM EST · 1 year ago NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
Nov 26, 2024, 7:00 AM EST · 1 year ago NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
Nov 19, 2024, 8:05 AM EST · 1 year ago Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
Nov 7, 2024, 4:05 PM EST · 1 year ago NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
Nov 5, 2024, 4:05 PM EST · 1 year ago NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
Oct 4, 2024, 9:05 AM EDT · 2 years ago NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
Sep 16, 2024, 8:05 AM EDT · 2 years ago NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
Jun 20, 2024, 4:10 PM EDT · 2 years ago NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
May 30, 2024, 4:05 PM EDT · 2 years ago NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
May 2, 2024, 4:05 PM EDT · 2 years ago NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
Apr 24, 2024, 4:05 PM EDT · 2 years ago NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
Apr 8, 2024, 7:00 AM EDT · 2 years ago NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Apr 4, 2024, 7:05 AM EDT · 2 years ago NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
Apr 2, 2024, 7:00 AM EDT · 2 years ago NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
Mar 21, 2024, 8:55 AM EDT · 2 years ago NextCure Provides Business Update and Reports Full Year 2023 Financial Results
Mar 5, 2024, 8:05 AM EST · 2 years ago NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
Jan 18, 2024, 4:05 PM EST · 2 years ago NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
Dec 21, 2023, 7:05 AM EST · 2 years ago NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
Nov 20, 2023, 7:00 AM EST · 2 years ago NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
Nov 15, 2023, 4:05 PM EST · 2 years ago NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
Nov 2, 2023, 4:05 PM EDT · 2 years ago NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results